Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma
Weiling Zhou,Weijing Li,Cuiying He,Ruijuan Ma,Qian Gao,Yuan Wang,Lei Feng,Lihong Liu
DOI: https://doi.org/10.2147/DMSO.S370017
2022-07-13
Abstract:Weiling Zhou, 1 Weijing Li, 2 Cuiying He, 2 Ruijuan Ma, 2 Qian Gao, 1 Yuan Wang, 1 Lei Feng, 1 Lihong Liu 2 1 Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital), Shijiazhuang, People's Republic of China; 2 Department of Hematology, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital), Shijiazhuang, People's Republic of China Correspondence: Lihong Liu, Department of Hematology, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital), Shijiazhuang, People's Republic of China, Tel +86 13831177920, Email Purpose: To explore the effects of primary and secondary hyperglycemia and the application of the hypoglycemic drug metformin on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Methods: We performed a retrospective analysis of 1767 DLBCL patients.Cox regression method was used for analysis to evaluate the prognostic factors, and the Kaplan-Meier method was used to draw a survival curve to analyze the effect of hyperglycemia and the hypoglycemic drug metformin on the progression-free survival (PFS) and overall survival (OS) of DLBCL patients. Results: Our study showed that patients with hyperglycemia tend to have higher age (age> 60 years), high body mass index (BMI)(≥ 24kg/m 2 ), late Ann Arbor stage (III–IV), high international prognostic index (IPI) (3– 5 score), high lactic dehydrogenase (LDH) level (> 250U/L), bulky disease and comorbidity. Hyperglycemia affects the survival time of the DLBCL population (PFS: adjusted HR 1.41, 95% CI: 1.16– 1.70, P < 0.001, OS: adjusted HR 1.33, 95% CI:1.09– 1.61, P=0.004).Compared with the non-hyperglycemia group, the secondary hyperglycemia increase affects the prognosis of the DLBCL population (P< 0.001). Compared with the secondary hyperglycemia group, the primary hyperglycemia group has a poor prognosis (P< 0.05). For patients with DLBCL and hyperglycemia (732 patients in total), the use of metformin can improve their PFS and OS (PFS: adjusted HR 0.69, 95% CI: 0.49– 0.96, P=0.028, OS: adjusted HR 0.68, 95% CI: 0.49– 0.95, P=0.024). Conclusion: Hyperglycemia and secondary hyperglycemia are related to the poor prognosis of DLBCL population.For patients with DLBCL combined with hyperglycemia, the application of metformin can improve survival rate. Keywords: hyperglycemia, diffuse large B-cell lymphoma, metformin, recrudescence, death, prognosis Lymphoma is a malignant tumor of the immune system that originates in lymph nodes and lymph node tissues. According to histopathological changes, it can be divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, with an annual incidence of approximately 24% of NHL. 1 Diabetes mellitus (DM) is a metabolic syndrome mainly manifested by chronic blood glucose elevation caused by the combined action of genetic and environmental factors. The number of people aged 20–79 years with diabetes worldwide has already reached 537 million in 2021 according to International Diabetes Federation, and this number is predicted to rise to 643 million by 2030 and 783 million by 2045. 2 Studies have shown that diabetes is associated with an increased risk of multiple tumors in the liver, pancreas, endometrium, colorectal, breast, and bladder. 3–9 Diabetes is associated with a higher risk of hematological malignancies, and is an independent risk factor for all-cause and specific cause mortality. 10 Studies have shown that DM is associated with an increased risk of NHL. 11,12 Metformin is a common hypoglycemic drug. Many studies have shown that the use of metformin in diabetic patients can reduce the incidence of cancer or reduce the mortality rate associated with cancer. 13–17 Metformin inhibits tumor growth, proliferation, invasion and metastasis by decreasing blood glucose levels, attenuating insulin resistance, reducing inflammation and improving the tumor microenvironment. 14 However, whether hyperglycemia, especially secondary hyperglycemia, affects the prognosis of DLBCL has not yet been reported, and there are few reports on whether metformin can help improve the prognosis of DLBCL patients.We aim to clarify the impact of hyperglycemia and the application of the hypoglycemic drug metformin on the prognosis of patients with DLBCL. A retrospective collection of 1767 patients diagnosed with DLBCL in the Department of Hematology, the Fourth Hospital of Hebei Medical University from January 1, 2010 to June 1, 2020, all met the diagnostic criteria for DLBCL. Informed consent wa -Abstract Truncated-
endocrinology & metabolism